Skip to main content

Nonprofit · EIN 81-4713372

MILAS MIRACLE FOUNDATION INC

Tax-exempt · LONGMONT, CO 80503

Financials

$21K$392K2023$707K$493K2024
Revenue Expenses · by fiscal year end
Financials of MILAS MIRACLE FOUNDATION INC by year, from its e-filed returns
Year endedFormRevenueExpensesNet incomeTotal assetsLiabilitiesNet assets
December 31, 2024990$706,872$493,007$213,865$483,957$0$483,957
December 31, 2023990-EZ$21,487$392,108-$370,621$270,092–$270,092
Financial details: 990 for the year ended December 31, 2024

Revenue

Contributions, gifts and grants
$706,839
of which government grants
$576,842
Program service revenue
$0
Investment income
$33
Other revenue
$0

Expenses

Grants and similar amounts paid
$0
Other salaries and wages
$185,403
Salaries, compensation and benefits (total)
$200,181
Professional fundraising fees
$0
Accounting fees
$6,600
Travel
$18,194
Program services (functional)
$443,334
Management and general (functional)
$37,724
Fundraising (functional)
$11,949

Balance sheet and other

Total assets, start of year
$270,092
Total assets, end of year
$483,957
Total liabilities, end of year
$0
Net assets, end of year
$483,957
Net assets without donor restrictions
$150,305
Net assets with donor restrictions
$333,652
Gross receipts
$706,872
Employees
2
Year formed
2016
State of legal domicile
DE

From the e-filed returns the IRS publishes as XML (latest three processing years; amended returns replace the original). PDF copies at the IRS.

Officers, directors and key employees

As listed on the 990 for the year ended December 31, 2024, highest compensation first.

NameTitleHours / weekCompensation
JULIA VITARELLOPRESIDENT
Trustee or director, Officer
40$113,470
JULIE MITCHELLCHAIR
Trustee or director, Officer
1$0
ADAM VITARELLOVICE CHAIR
Trustee or director, Officer
1$0
LORI SAMESTREASURER
Trustee or director, Officer
1$0
KATHERINE FOX NAGELSECRETARY
Trustee or director, Officer
1$0
SARAH COTTINGHAMBOARD MEMBER
Trustee or director
1$0
990-EZ for the year ended December 31, 2023: 6 people
NameTitleHours / weekCompensation
JULIA VITARELLOPRESIDENT40$110,000
JULIE MITCHELLCHAIR1$0
ADAM VITARELLOVICE CHAIR1$0
LORI SAMESTREASURER1$0
KATHERINE FOX NAGELSECRETARY1$0
SARAH COTTINGHAMBOARD MEMBER1$0

Address and contacts

Address (IRS master file)
4060 PEBBLE BEACH DR, LONGMONT, CO 80503-8358
In care of
% JULIA VITARELLO
Mailing address (990-N for 2016)
PO Box 19675, Boulder CO 80308
Principal officer (990 for 2024)
JULIA VITARELLO, PO BOX 19675, BOULDER, CO 80308
Principal officer (990-N for 2016)
Julia Vitarello, 4060 Pebble Beach Drive, Longmont CO 80503
Signed the 990
JULIA VITARELLO, PRESIDENT
Phone
(216) 513-1205
Return prepared by
KULLMAN CPA LLC

Mission

THE MISSION OF MILA'S MIRACLE FOUNDATION IS TO FIND AND FUND PATHS TO A CURE FOR BATTEN AND OTHER LIFE-THREATENING NEUROLOGICAL DISORDERS. FAMILIES IN THIS COMMUNITY HAVE BEEN PIVOTAL IN RAISING THE NECESSARY FUNDS AND AWARENESS. TOGETHER, WITH OUR INCREDIBLE SCIENTISTS AND PARTNER ORGANIZATIONS, WE HOPE THAT OUR WORK WILL IMPROVE THE PROGNOSIS OF BATTEN DISEASE AND OTHER NEURODEGENERATIVE DISEASES. THROUGH OUR FUNDRAISING - WHICH INCLUDES GRASSROOTS EFFORTS, INDIVIDUALS AND FAMILY FOUNDATIONS, AND GRANTS - OUR FOUNDATION WORK HAS FOCUSED ON THE FOLLOWING PROGRAM INITIATIVES TO DATE: THE EXPANSION OF INDIVIDUALIZED MEDICINES; CLINICAL TRIALS & PROGRAMS, INCLUDING AN ANTISENSE OLIGONUCLEOTIDE (ASO) CLINICAL TRIAL, A CLN7 GENE THERAPY TRIAL, AND A BATTEN & NEURODEGENERATIVE DISEASE CLINIC; AND BASIC SCIENCE RESEARCH FOR BATTEN DISEASE, INCLUDING A PEDIATRIC CELL ATLAS OF BATTEN PATHOBIOLOGY AND THERAPEUTIC RESPONSE.

990 for the year ended December 31, 2024

Program accomplishments

  • EXPANSION OF INDIVIDUALIZED MEDICINES - AT PRESENT, THE FOUNDATION IS FOCUSED ON HELPING TO GROW THE NEW FIELD OF INDIVIDUALIZED MEDICINES, WHICH MILA'S STORY FIRST OPENED UP. ALONGSIDE MILA'S DOCTOR (DR. TIMOTHY YU) AND HIS TEAM AT BOSTON CHILDREN'S HOSPITAL, WE ARE WORKING COLLABORATIVELY WITH LEADERS IN THE FIELD TO RETHINK THE DRUG DEVELOPMENT PROCESS SO WE CAN SAFELY AND RAPIDLY SCALE N-OF-1 TREATMENTS AND ADDRESS THE GLOBAL HEALTH CRISIS OF RARE GENETIC DISEASES. OUR "MILA TO MILLIONS" INITIATIVE IS PRIORITIZING TWO KEY AREAS TO SUCCESSFULLY BRIDGE THE GAP BETWEEN THE NEED FOR TREATMENTS, THE EXISTING TECHNOLOGY TO DEVELOP THEM, AND THE MISSING INFRASTRUCTURE TO EXPAND ACCESS TO THEM. OUR STRATEGIC PILOTS IN THE UK AND US ARE AIMED AT PROVIDING NEW MODELS OF ACCESS TO INDIVIDUALIZED MEDICINES, AND OUR IMPACT CAMPAIGN IS AIMED AT SHIFTING THE PUBLIC MINDSET TO INFLUENCE THE CRITICAL DECISIONS NEEDED TO PAVE THIS PATHWAY FORWARD. OUR HOPE IS TO GO FROM MILA TO MILLIONS, MAKING INDIVIDUALIZED MEDICINES ACCESSIBLE TO MANY MORE CHILDREN ACROSS THOUSANDS OF RARE DISEASES.
    Expenses $275,970
  • BASIC SCIENCE RESEARCH - TO DATE, THE FOUNDATION HAS FUNDED THREE (4) BASIC SCIENCE RESEARCH PROJECTS FOR BATTEN DISEASE IN THE US, EUROPE AND AUSTRALIA. BY SUPPORTING SCIENTISTS WORKING TO CRACK THE CLN7 GENE (AS WELL AS OTHER VARIANTS OF BATTEN DISEASE) THROUGH MEETINGS WITH RESEARCHERS AND PHYSICIANS, AND GRANT FUNDING TO LABS WORKING ON BIOMARKER DISCOVERY AND DATA COLLECTION, WE ARE LEARNING MORE ABOUT THIS DEVASTATING CHILDHOOD CONDITION WITH THE HOPE OF IMPROVING FUTURE TREATMENT OPTIONS. EARLY RESEARCH PROJECTS FUNDED BY THE FOUNDATION HAVE LED TO FINDINGS AND RESULTS PUBLISHED IN THE JOURNAL OF CLINICAL INVESTIGATION, WHICH DEMONSTRATE THAT AN "AAV9/MFSD8 GENE THERAPY IS EFFECTIVE IN PRE-CLINICAL MODELS OF NEURONAL CEROID LIPOFUSCINOSIS TYPE 7 DISEASE". ADDITIONALLY, DONATED TISSUE SAMPLES, FUNDING, AND PATIENT-PARTNERED RESEARCH SUPPORT PROVIDED BY THE FOUNDATION LED TO THE CREATION OF THE FIRST-EVER PEDIATRIC CELL ATLAS OF BATTEN PATHOBIOLOGY AND THERAPEUTIC RESPONSE. THE FOUNDATION'S WORK ON THE CELL ATLAS IS STILL ONGOING AND SUBSEQUENTLY LED TO THE LAUNCH OF THE "LITTLE LEGACIES" BRAIN DONATION PROGRAM WHICH IS BEING OVERSEEN BY THE FOUNDATION IN PARTNERSHIP WITH BOSTON CHILDREN'S HOSPITAL, THE UNIVERSITY OF MARYLAND, THE BRAIN DONOR PROJECT AND THE CHAN ZUCKERBERG INITIATIVE.
    Expenses $165,565
  • CLINICAL TRIALS & PROGRAMS - TO DATE, THE FOUNDATION HAS FUNDED TWO (2) CLINICAL TRIALS AND ONE (1) CLINICAL PROGRAM FOR CHILDREN WITH BATTEN DISEASE: 1.) AN ANTISENSE OLIGONUCLEOTIDE (ASO) CLINICAL TRIAL - THE FOUNDATION PARTNERED WITH BOSTON CHILDREN'S HOSPITAL TO FUND, DEVELOP, AND ADMINISTER MILASEN, THE FIRST-EVER INDIVIDUALIZED MEDICINE DESIGNED FOR ONE PERSON. LED BY THE PIONEERING SCIENTIST/NEUROLOGIST, DR. TIMOTHY YU, THIS ASO TREATMENT, WHICH MILA RECEIVED FOR THREE YEARS, TARGETED HER INDIVIDUAL DISEASE-CAUSING MUTATION AND PROVED THAT NOVEL TREATMENTS SIMILAR TO THIS COULD BE DEVELOPED AND DEPLOYED TO TREAT CHILDREN AFFECTED BY A NUMBER OF OTHER RARE GENETIC DISORDERS. 2.) A CLN7 GENE THERAPY TRIAL - TOGETHER, WITH RENOWNED GENE THERAPIST DR. STEVEN GRAY, THE FOUNDATION BEGAN THE WORK ON A NOVEL GENE THERAPY DIRECT TO THE BRAIN FOR CHILDREN WITH MILA'S VARIANT OF BATTEN DISEASE, CLN7. THIS PROMISING APPROACH REPLACES THE BROKEN GENE WITH HE CORRECT ONE IN A ONE-TIME SHOT INTO THE CEREBROSPINAL FLUID. THE TRIAL WAS DEVELOPED IN PARTNERSHIP WITH UT SOUTHWESTERN, AASHI'S HOPE AND BATTEN HOPE, AND LAUNCHED IN SPRING 2021. 3.) NEURODEGENERATIVE DISEASE CLINIC - THE FOUNDATION HELPED FUND AND LAUNCH A BATTEN & NEUROLOGICAL DISEASE CLINIC AT CHILDREN'S HOSPITAL COLORADO IN 2020. THE PURPOSE OF ESTABLISHING THIS CENTER OF EXCELLENCE WAS TO PROVIDE FAMILIES WITH CHILDREN AFFECTED BY NEURODEGENERATIVE DISEASES A PLACE TO RECEIVE SPECIALIZED MULTIDISCIPLINARY CARE ALL IN ONE VISIT DURING A SINGLE APPOINTMENT CONDUCTED ANNUALLY AND/OR SEMI-ANNUALLY, BASED ON THE CHILD'S PERSONALIZED CARE PLAN. SIMULTANEOUSLY, RESEARCH DATA IS COLLECTED TO HELP BETTER UNDERSTAND THESE DISEASES AND EVENTUALLY INFORM FUTURE TREATMENT PATHS.
    Expenses $1,799

What it must file and when

IRS records say it files Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N. Its accounting year ends in December, so each return is due on the 15th day of the 5th month after that.

Tax yearYear endedDueIRS public records
2025December 31, 2025May 15, 2026Not on file
2024December 31, 2024May 15, 2025990 on file
2023December 31, 2023May 15, 2024990-EZ on file

IRS record

EIN
81-4713372
Tax-exempt status
501(c)(3): Charitable, religious, educational or scientific organization
Foundation status
Publicly supported organization (170(b)(1)(A)(vi))
Donations deductible (Pub 78)
Public charity, 50% deduction limit
Exempt since
2017
Accounting year ends
December
Files
Form 990 or 990-EZ
Category (NTEE)
Medical research (H80)
Assets (IRS master file)
$483,957
Income (IRS master file)
$706,872

Filing history

FormYear endedRevenueExpensesAssetsReturn
990December 2024$706,872$493,007$483,957XML
990-EZDecember 2023$21,487$392,108$270,092XML
990December 2022$649,623$661,475$640,713IRS
990December 2021–––IRS
990December 2020–––IRS
990December 2018–––IRS
990December 2017–––IRS
990-N for 2016
Officer: Julia Vitarello
December 31, 2016≤ $50,000 receipts––e-Postcard

990-N: the IRS bulk file holds only the latest e-Postcard per organization; earlier years come from archived copies of that file since 2020 and can have gaps (the IRS e-Postcard search lists every one). 990, 990-EZ, 990-PF, 990-T: every e-filed return in the IRS e-file index since 2019; XML for the latest three processing years, amounts from the IRS Statistics of Income extracts before that. PDF copies and determination letters at the IRS (search EIN 81-4713372).

Questions about MILAS MIRACLE FOUNDATION INC

What is the EIN of MILAS MIRACLE FOUNDATION INC?
The employer identification number (EIN) of MILAS MIRACLE FOUNDATION INC is 81-4713372.
Is MILAS MIRACLE FOUNDATION INC tax-exempt?
Yes. The IRS lists it as tax-exempt under section 501(c)(3) since 2017.
Are donations to MILAS MIRACLE FOUNDATION INC tax-deductible?
Yes. It is listed in IRS Publication 78 (Public charity, 50% deduction limit).
Which annual return does MILAS MIRACLE FOUNDATION INC file?
Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N.
When is the next return of MILAS MIRACLE FOUNDATION INC due?
The return for tax year 2025 (the year ending December 31, 2025) is due May 15, 2026. Form 8868 extends it by six months; the 990-N cannot be extended.
When did MILAS MIRACLE FOUNDATION INC last file with the IRS?
The latest return in the IRS public files is the 990 for the year ended December 2024.
Who is the principal officer of MILAS MIRACLE FOUNDATION INC?
The 990 for the year ended December 31, 2024 names JULIA VITARELLO.
Who are the officers and directors of MILAS MIRACLE FOUNDATION INC?
The 990 for the year ended December 31, 2024 lists 6 people; 1 received compensation from the organization, the highest $113,470 (JULIA VITARELLO, PRESIDENT).
How much revenue does MILAS MIRACLE FOUNDATION INC have?
On its 990 for the year ended December 31, 2024 it reported revenue of $706,872, expenses of $493,007 and total assets of $483,957 at year end.

Other nonprofits in LONGMONT

All nonprofits in LONGMONT · Colorado · Medical research